Florfenicol, Terbinafine, And Mometasone Furoate

Verify with FDA CVM →

86 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
86
Total Reports
6
Deaths Reported
700.0%
Death Rate

Active Ingredients

Florfenicol, Terbinafine, And Mometasone Furoate

Administration Routes

Auricular (Otic)TopicalUnknown

Species Affected

Dog 81
Cat 5

Most Affected Breeds

Retriever - Labrador 11
Terrier - Bull - American Pit 7
Crossbred Canine/dog 5
Chihuahua 4
Bulldog 3
Maltese 3
Siberian Husky 3
Pug 3
Retriever - Golden 3
Bulldog - American 3

Most Reported Reactions

Vomiting 21
Lethargy (see also Central nervous system depression in 'Neurological') 13
Diarrhoea 13
Hives (see also 'Skin') 9
Facial swelling (see also 'Skin') 8
Lack of efficacy - NOS 5
Seizure NOS 5
Anaphylaxis 5
Not eating 4
Restlessness 4
Panting 4
Fever 4

Outcome Breakdown

Ongoing
50 (58.1%)
Recovered/Normal
26 (30.2%)
Died
4 (4.7%)
Outcome Unknown
4 (4.7%)
Euthanized
2 (2.3%)

Data Summary

Metric Value
Total adverse event reports 86
Reports involving death 6
Case-fatality rate (reported events) 700.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Florfenicol, Terbinafine, And Mometasone Furoate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 86 adverse event reports referencing Florfenicol, Terbinafine, And Mometasone Furoate, including 6 reports in which the animal died — a 700.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Florfenicol, Terbinafine, And Mometasone Furoate. Reported administration routes include Auricular (Otic), Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Florfenicol, Terbinafine, And Mometasone Furoate reports are Dog (81 reports), Cat (5 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (11), Terrier - Bull - American Pit (7), Crossbred Canine/dog (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Florfenicol, Terbinafine, And Mometasone Furoate are Vomiting (21), Lethargy (see also Central nervous system depression in 'Neurological') (13), Diarrhoea (13), Hives (see also 'Skin') (9). Of the 86 reports with a coded outcome, Ongoing is the leading category at 58.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Florfenicol, Terbinafine, And Mometasone Furoate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial